Self-administering retatrutide outside a clinical trial carries serious risks including infection, product impurity, incorrect dosing, and lack of pharmacovigilance protection
It activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
SURMOUNT-1 trial suggests that tirzepatide may have a promising future as a therapy for obesity, HF, and non-alcoholic fatty liver disease (NAFLD) [5, 8]
Toujeo does carry a somewhat lower hypoglycemia risk compared to Lantus, thanks to its more gradual absorption profile
Knowing what your medication should look like helps you identify potential quality issues
Does Ozempic Help Osteoarthritis and Knee Pain